Mixed Connective Tissue Disease Associated with Protein Losing Enteropathy: Successful Treatment with Intravenous Cyclophosphamide Therapy.
スポンサーリンク
概要
- 論文の詳細を見る
A patient with mixed connective tissue disease who developed protein losing enteropathy (PLE) is described. The PLE and other symptoms improved dramatically after monthly intravenous administration of 700 mg/day cyclophosphamide three times combined with oral prednisolone, while they were ineffective to the treatment with intravenous methyl-prednisolone 500 mg per day for 3 days. The serum level of CA125 antigen paralleled the severity of symptoms, signs and laboratory data associated with PLE. Thus, pleural effusion, ascites, edema and hypoalbuminemia improved along with the decrease in the level of CA125, suggesting that CA125 might be a marker of the activity of PLE.(Internal Medicine 31 : 1359-1362, 1992)
- 社団法人 日本内科学会の論文
著者
-
DEMURA Hiroshi
The Second Department of Medicine, Tokyo Women's Medical College
-
SUZUKI Takahiro
the Institute of Rheumatology, Tokyo Women's Medical College
-
Kashiwazaki Sadao
The Institute Of Rheumatology Tokyo Women's Medical College
-
SATO Kanji
the Second Department of Internal Medicine, Tokyo Women's Medical College
-
ONODA Noritaka
the Second Department of Internal Medicine, Tokyo Women's Medical College
-
FURUYA Takefumi
the Second Department of Internal Medicine, Tokyo Women's Medical College
-
TAMURA Kazuko
the Second Department of Internal Medicine, Tokyo Women's Medical College
関連論文
- Renin/Angiotensin/Aldosterone System in Malignant Hypertension
- Variant Forms of Primary Aldosteronism: Reconsideration of the Differential Diagnosis and Treatment
- Intravenous Immunoglobulin Therapy for Refractory Myositis
- Adult Still's Disease with Myocarditis and Peritonitis.
- Fatal Pneumomediastinum in Dermatomyositis without Creatine Kinase Elevation.
- Sjögren''s Syndrome in One of Two Sisters with Idiopathic Renal Hypouricemia
- Mixed Connective Tissue Disease Associated with Protein Losing Enteropathy: Successful Treatment with Intravenous Cyclophosphamide Therapy.